To characterize immunosuppressive neutrophils, particularly PMN-MDSCs, using multi-omics approaches and to emphasize the critical role of functional testing in cancer treatment.
Key Findings:
PMN-MDSCs exhibit immunosuppressive activity, contributing to tumor growth and poor prognosis, highlighting the need for targeted interventions.
Low-density neutrophils (LDNs) have been identified as a subset with immunosuppressive capacity, accumulating with cancer progression, which may serve as a therapeutic target.
Neutrophil density is influenced by granular composition and cellular age, affecting the identification of immunosuppressive subsets and their clinical relevance.
Interpretation:
The study highlights the complexity of neutrophil subsets in cancer and the need for advanced techniques to accurately characterize their immunosuppressive functions, which could lead to improved therapeutic strategies.
Limitations:
Current methods have not led to a clear immunophenotypic characterization of PMN-MDSCs, complicating their clinical application.
Functional testing of neutrophil subsets remains insufficient to establish clinical relevance, posing a barrier to effective treatment strategies.
Conclusion:
Further development of single-cell techniques is essential for accurately defining neutrophil subsets and understanding their roles in cancer immunosuppression, which is crucial for advancing cancer therapies.
